LXXGF - LXXGF STOCK NEWS

LexaGene Holdings, Inc. (OTCQB: LXXGF) has successfully detected anthrax spores using its MiQLab™ System, advancing its Cooperative Research and Development Agreement with the U.S. Army’s DEVCOM. This testing phase aims to evaluate sensitivity and quantitative capabilities for biothreat detection, with studies commencing around November 15, 2021. The MiQLab is designed for automated multiplex PCR testing, facilitating rapid detection of pathogens. Company representatives emphasize the robustness of their sample preparation in detecting dormant spores, crucial for biothreat response.

LexaGene Holdings (OTCQB: LXXGF) has been honored as a Best in Show Spotlight company at the upcoming Petcare Innovation Summit in Boston. The company, known for its MiQLab System which streamlines veterinary diagnostics, aims to enhance decision-making in antimicrobial prescriptions. Dr. Jack Regan, CEO, highlighted the growing demand in the veterinary industry driven by increased pet ownership since the pandemic. The MiQLab offers rapid results in approximately two hours, addressing the needs of overwhelmed veterinarians and improving animal care efficiency.

LexaGene Holdings, OTCQB: LXXGF, announced a corporate update for investors on November 3, 2021, at 12:00 p.m. (EST). Dr. Jack Regan, CEO, will discuss the company's developments since the last update and the progress of the MiQLab™ System, which offers rapid multiplex PCR testing for veterinary diagnostics. Investors can secure an invitation by RSVPing to IR@LexaGene.com by November 2, 2021. LexaGene aims to enhance its market presence across various sectors, including veterinary diagnostics and biopharmaceutical manufacturing.

LexaGene Holdings, Inc. (OTCQB: LXXGF) has completed its analytical studies needed for an FDA Emergency Use Authorization (EUA) application for its MiQLab™ system for COVID-19 diagnostics. The company is now preparing for a clinical evaluation to compile and submit data to the FDA. Dr. Jack Regan, CEO, stated that this milestone could greatly impact syndromic testing for multiple diseases beyond COVID-19. The MiQLab is unique as a flow-through PCR system, though the FDA may request additional studies before authorizing it for human diagnostics.

LexaGene Holdings announced successful results from its MiQLab System, a diagnostic tool that accurately identifies bacteria and predicts antimicrobial resistance at the point of care. The technology achieved over 99% agreement in pathogen identification and high accuracy in drug resistance detection. With projections indicating that drug-resistant pathogens could cause over 10 million deaths annually within 30 years, the MiQLab aims to aid veterinarians in providing timely, evidence-based care while minimizing antibiotic overuse, thereby improving patient outcomes and veterinarian morale.

LexaGene Holdings (OTCQB: LXXGF; TSX-V: LXG) announced that Dr. Jack Regan, CEO and Founder, will present live at Virtual Investor Conferences on October 7, 2021, at 3:00 p.m. ET. The event invites investors to engage with the company in real-time. A recorded version will be available post-event for those unable to join live. Recent highlights include partnership agreements and advancements in their MiQLab PCR system, which provides rapid, accurate results in approximately two hours, enhancing diagnostic capabilities in various sectors.

LexaGene Holdings, Inc. (OTCQB: LXXGF) announced its participation in three investor conferences in early October 2021, aimed at updating current investors and attracting new ones. CEO Dr. Jack Regan highlighted the innovation in their MiQLab™ system, which offers rapid in-clinic PCR testing for veterinary diagnostics. The company will present at BioFuture 2021 (Oct 5-6), Lytham Partners Fall 2021 Investor Conference (Oct 5-7), and Small Cap Growth Virtual Investor Conference (Oct 7). LexaGene's technology aims to enhance veterinary care through increased adoption across hospitals.

LexaGene Holdings, Inc. (OTCQB: LXXGF) announced positive outcomes from three veterinary conferences in September 2021. The Company generated over 750 leads and showcased its innovative MiQLab® System, which automates PCR testing for pathogen identification and antimicrobial resistance detection. CEO Dr. Jack Regan emphasized the strong interest from veterinary health leaders and revealed ongoing sales discussions with corporate accounts. LexaGene aims to position itself as a market leader in in-clinic infectious disease testing.

LexaGene Holdings has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army’s Combat Capabilities Development Command (DEVCOM) to develop biothreat detection capabilities. The agreement involves testing LexaGene's MiQLab system for its ability to detect anthrax and plague pathogens. This collaboration aims to enhance the U.S. government's biothreat detection technology, leveraging DEVCOM's unique samples and facilities. LexaGene seeks to demonstrate the benefits of its open-access MiQLab technology for rapid bio-threat detection.